Christina Furebring
Alligator Bioscience, Sweden
Posters-Accepted Abstracts: Immunome Res
Alligator Bioscience has developed a fully human agonistic CD40 antibody, ADC-1013, optimized for tumor directed immunotherapy by increasing potency and tumor retention. A multicenter phase I study evaluating intratumoral administration of ADC-1013 will be initiated early 2015. Further, Alligator Bioscience�´s concept for generating next generation bi-specific immune modulatory antibodies for tumor directed immune activation will also be presented. In order to establish safe and effective immunotherapy, also for earlier stages of cancer and to enable combination of immune modulatory drugs, it will be essential not only to increase the response rate but also to decrease toxicity. Alligator Bioscience�´s strategy to develop tumor directed mono and bi-specific immune modulators, thereby optimizing the effect and minimizing immune related adverse events, will be presented. This presentation will help understanding how administration route and other approaches to direct the immune response towards the tumor can be obtained with mono and bispecific antibodies.
Email: chf@alligatorbioscience.com
